Author/Editor | Goldhirsch, A; Lindtner, J; Eržen, D; Majdič, E; Štabuc, B; Plesničar, A; Golouh, R; Lamovec, J; Jančar, J; Vrhovec, I; Kramberger, M | |
Title | Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial | |
Type | članek | |
Source | J Natl Cancer Inst | |
Vol. and No. | Letnik 95, št. 24 | |
Publication year | 2003 | |
Volume | str. 1833-46 | |
Language | eng | |
Abstract | Background: Although chemotherapy and ovarian function suppression are both effective adjuvant therapies for patients with early-stage breast cancer, little is known of the efficacy of their sequential combination. In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node-negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone. Methods: From March 1990 through October 1999, 1063 patients stratified by estrogen receptor (ER) status and radiotherapy plan were randomly assigned to receive goserelin for 24 months (n = 346), six courses of "classical" CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or six courses of classical CMF followed by 18 months of goserelin (CMF --> goserelin; n = 357). A fourth arm (no adjuvant treatment) with 46 patients was discontinued in 1992. Tumors were classified as ER-negative (30%), ER-positive (68%), or ER status unknown (3%). Twenty percent of patients were aged 39 years or younger. The median follow-up was 7 years. The primary outcome was diseasefree survival (DFS). Results: Patients with ER-negative tumors achieved better disease-free survival if they received CMF (5-year DFS for CMF = 84%, 95% confidence interval [CI] = 77% to 91%; 5-year DFS for CMF --> goserelin = 88%, 95% CI = 82% to 94%) than if they received goserelin alone (5-year DFS = 73%, 95% CI = 64% to 81%). By contrast, for patients with ER-positive disease, chemotherapy alone and goserelin alone provided similar outcomes (5-year DFS for both treatment groups = 81%, 95% CI = 76% to 87% ), whereas sequential therapy (5-year DFS = 86%, 95% CI = 82% to 91% ) provided a statistically nonsignificant improvement compared with either modality alone, primarily because of the results among younger women. (Abstract truncated at 2000 characters). | |
Descriptors | BREAST NEOPLASMS ANTINEOPLASTIC AGENTS, HORMONAL ANTINEOPLASTIC AGENTS, COMBINED GOSERELIN METHOTREXATE ADULT MIDDLE AGE TREATMENT OUTCOME INCIDENCE SURVIVAL ANALYSIS RECEPTORS, ESTROGEN AMENORRHEA LYMPHATIC METASTASIS CHEMOTHERAPY, ADJUVANT CONFIDENCE INTERVALS PREMENOPAUSE FLUOROURACIL |